India vs Jordan: The number of people with susceptibility test result for rifampicin
India
76.27
in 2021
Jordan
78.48
in 2021
India rank
98th
Jordan rank
97th
The number of people with susceptibility test result for rifampicin over time
- India
- Jordan
How they compare
Jordan currently reports 78.48 against 76.27 in India, a difference of 2.21.
Across all 5 years both countries report, Jordan has been ahead every year.
India ranks 98th and Jordan ranks 97th of 146 countries.
Jordan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Jordan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 51.98 | 73.8 | 21.83 | Jordan |
| 2020s | 87.02 | 89.24 | 2.22 | Jordan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, India or Jordan?
- Jordan, at 78.48 against 76.27 in India as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between India and Jordan?
- 2.21, with Jordan ahead.
- How many years of comparable data are there for India and Jordan?
- 5 years are reported by both, from 2017 to 2021.
- How do India and Jordan rank globally for the number of people with susceptibility test result for rifampicin?
- India ranks 98th and Jordan ranks 97th of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.